Upgrade to SI Premium - Free Trial

Engene (ENGN)

1.89 +0.04 (2.16%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (9/16/26)

Latest Headlines

Form 3 enGene Therapeutics Inc. For: Jul 16 Filed by: Chinoporos Constantine July 22, 2026 4:06 PM - SEC Filing Form 3 enGene Therapeutics Inc. For: Jul 16 Filed by: Richton Kathleen P. July 22, 2026 4:06 PM - SEC Filing Form SCHEDULE 13G enGene Therapeutics Inc. Filed by: ACORN BIOVENTURES, L.P. July 22, 2026 9:14 AM - SEC Filing Form 8-K enGene Therapeutics Inc. For: Jul 17 July 17, 2026 4:06 PM - SEC Filing Form 8-K enGene Therapeutics Inc. For: Jul 15 July 16, 2026 8:07 AM - SEC Filing enGene names new board chairman ahead of planned BLA filing July 16, 2026 8:01 AM - StreetInsider enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones July 16, 2026 8:00 AM - BizWire Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman July 15, 2026 9:00 AM - Globe NewsWire Form 8-K/A enGene Therapeutics Inc. For: Jun 16 June 18, 2026 4:06 PM - SEC Filing Morgan Stanley Downgrades Engene Holdings Inc. (ENGN) to Underweight June 18, 2026 2:37 AM - StreetInsider Form 4 enGene Therapeutics Inc. For: Jun 16 Filed by: Astley-Sparke Philip June 17, 2026 5:44 PM - SEC Filing Form 4 enGene Therapeutics Inc. For: Jun 16 Filed by: BRUNK GERALD A June 17, 2026 5:43 PM - SEC Filing Form 4 enGene Therapeutics Inc. For: Jun 16 Filed by: Glickman Richard M June 17, 2026 5:42 PM - SEC Filing Form 4 enGene Therapeutics Inc. For: Jun 16 Filed by: Grossman William June 17, 2026 5:41 PM - SEC Filing Form 4 enGene Therapeutics Inc. For: Jun 16 Filed by: HASTINGS PAUL J June 17, 2026 5:40 PM - SEC Filing Form 4 enGene Therapeutics Inc. For: Jun 16 Filed by: Heffernan Michael Thomas June 17, 2026 5:38 PM - SEC Filing Form 4 enGene Therapeutics Inc. For: Jun 16 Filed by: Zoth Lota S. June 17, 2026 5:38 PM - SEC Filing Form 4 enGene Therapeutics Inc. For: Jun 16 Filed by: Joustra Wouter June 17, 2026 5:37 PM - SEC Filing Engene Holdings Inc. (ENGN) PT Lowered to $4 at H.C. Wainwright June 16, 2026 6:09 AM - StreetInsider Form 10-Q enGene Therapeutics Inc. For: Apr 30 June 15, 2026 9:17 AM - SEC Filing Form 8-K enGene Therapeutics Inc. For: Jun 13 June 15, 2026 9:15 AM - SEC Filing enGene Reports Second Quarter 2026 Financial Results and Provides Business Update June 15, 2026 9:00 AM - BizWire Form 8-K enGene Therapeutics Inc. For: Jun 09 June 10, 2026 4:10 PM - SEC Filing Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Cormorant Asset Management, LP May 15, 2026 1:12 PM - SEC Filing Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: BML Investment Partners, L.P. May 14, 2026 10:30 AM - SEC Filing Engene Holdings Inc. (ENGN) PT Lowered to $2 at UBS May 14, 2026 8:54 AM - StreetInsider Form SCHEDULE 13G enGene Therapeutics Inc. Filed by: BML Investment Partners, L.P. May 13, 2026 9:23 PM - SEC Filing Form ARS enGene Therapeutics Inc. For: Oct 31 May 8, 2026 4:11 PM - SEC Filing Form DEF 14A enGene Therapeutics Inc. For: Jun 09 May 8, 2026 4:07 PM - SEC Filing enGene Therapeutics hit by analyst downgrades as drug data disappoints May 8, 2026 12:19 PM - StreetInsider Leerink Partners Downgrades Engene Holdings Inc. (ENGN) to Market Perform May 8, 2026 7:38 AM - StreetInsider Engene Holdings Inc. (ENGN) PT Lowered to $6 at H.C. Wainwright May 8, 2026 7:00 AM - StreetInsider Engene Holdings Inc. (ENGN) PT Lowered to $2 at Wells Fargo May 8, 2026 6:55 AM - StreetInsider Citizens Downgrades Engene Holdings Inc. (ENGN) to Market Perform May 8, 2026 3:49 AM - StreetInsider Raymond James Downgrades Engene Holdings Inc. (ENGN) to Outperform May 8, 2026 3:38 AM - StreetInsider Piper Sandler Downgrades Engene Holdings Inc. (ENGN) to Neutral May 8, 2026 3:36 AM - StreetInsider Oppenheimer Downgrades Engene Holdings Inc. (ENGN) to Perform May 8, 2026 2:45 AM - StreetInsider Guggenheim Downgrades Engene Holdings Inc. (ENGN) to Neutral May 8, 2026 2:33 AM - StreetInsider Form 8-K enGene Therapeutics Inc. For: May 05 May 7, 2026 7:11 AM - SEC Filing enGene reports 54% response rate in bladder cancer gene therapy trial May 7, 2026 7:01 AM - StreetInsider enGene Announces Updated Interim Results From LEGEND Pivotal Cohort May 7, 2026 7:00 AM - BizWire Form SCHEDULE 13G/A enGene Therapeutics Inc. Filed by: Invus Global Management, LLC May 5, 2026 10:59 AM - SEC Filing Piper Sandler Reiterates Overweight Rating on Engene (ENGN), 'under-the-radar NMIBC name' May 1, 2026 9:18 AM - StreetInsider Full Article List